More programs, more candles, more light.

Get the Flash Player to see this player.

Loading the player ...

Panel 3: Allan Robins, ViaCyte

CIRM Disease Team Reports

November 30, 2011
15 minutes
Allan Robins


Dr. Robins received a B.S. with honors in biochemistry and a Ph.D. in molecular biology from the University of Adelaide in Australia. He followed his studies with postdoctoral work at Cambridge University in England. In addition to his duties as acting CEO of ViaCyte, Dr. Robins oversees company-wide manufacturing activities along with research operations in Athens, Georgia. Prior to ViaCyte, Dr. Robins served as chief scientific officer at BresaGen, Inc., the United States subsidiary of BresaGen Limited, an Australian biotechnology company that has since been acquired by Hospira, Inc. Under Dr. Robin’s leadership, BresaGen, Inc. was awarded significant support for its stem cell research from the NIH. BresaGen merged with ViaCyte’s predecessor companies in 2004. Prior to BresaGen, Inc., Dr. Robins was chief scientific officer at BresaGen Limited, where he helped raise over $30 million and developed a proprietary expression system which continues to be used in the production of protein pharmaceuticals.